{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:31:05Z","timestamp":1767652265594,"version":"3.37.3"},"reference-count":52,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>\n          Introduction Many individuals with major depressive disorder (MDD) do not respond to initial antidepressant monotherapy. Adjunctive aripiprazole is recommended for treatment non-response; however, the impacts on quality of life (QoL) for individuals who receive this second-line treatment strategy have not been described.<\/jats:p><jats:p>\n          Methods We evaluated secondary QoL outcomes in patients with MDD (n=179). After 8 weeks of escitalopram, non-responders (&lt;50% decrease in clinician-rated depression) were treated with adjunctive aripiprazole for 8 weeks (n=97); responders continued escitalopram (n=82). A repeated-measures ANOVA evaluated change in Quality of Life Enjoyment and Satisfaction Short Form scores. QoL was described relative to normative benchmarks.<\/jats:p><jats:p>\n          Results Escitalopram responders experienced the most QoL improvements in the first treatment phase. For non-responders, QoL improved with a large effect during adjunctive aripiprazole treatment. At the endpoint, 47% of patients achieving symptomatic remission still had impaired QoL.<\/jats:p><jats:p>\n          Discussion Individuals who were treated with adjunctive aripiprazole after non-response to escitalopram experienced improved QoL, but a substantial degree of QoL impairment persisted. Since QoL deficits may predict MDD recurrence, attention to ways to support this outcome is required.<\/jats:p>","DOI":"10.1055\/a-1385-0263","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:01:29Z","timestamp":1614729689000},"page":"225-231","source":"Crossref","is-referenced-by-count":3,"title":["Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report"],"prefix":"10.1055","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6179-1983","authenticated-orcid":false,"given":"Emma","family":"Morton","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkat","family":"Bhat","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Giacobbe","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Lou","sequence":"additional","affiliation":[{"name":"Dalla Lane School of Public Health, University of Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin E.","family":"Michalak","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trisha","family":"Chakrabarty","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benicio N.","family":"Frey","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roumen V.","family":"Milev","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry and Psychology, Queen\u2019s University, Kingston, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar V.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Rotzinger","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidney H.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond W.","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the CAN-BIND Investigator Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e1001547","DOI":"10.1371\/journal.pmed.1001547","article-title":"Burden of depressive disorders by country, sex, age, and year: Findings from the Global Burden of Disease Study 2010","volume":"10","author":"A J Ferrari","year":"2013","journal-title":"PLoS Medicine"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11136-012-0187-6","article-title":"A descriptive analysis of quality of life using patient-reported measures in major depressive disorder in a naturalistic outpatient setting","volume":"22","author":"W W Ishak","year":"2013","journal-title":"Qual Life Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/10673229.2011.614099","article-title":"Quality of life: The ultimate outcome measure of interventions in major depressive disorder","volume":"19","author":"W W IsHak","year":"2011","journal-title":"Harv Rev Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments","volume":"61","author":"S H Kennedy","year":"2016","journal-title":"Can J Psychiatry"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881115581093","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines","volume":"29","author":"A Cleare","year":"2015","journal-title":"J Psychopharmacol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jad.2016.12.013","article-title":"The effect of treatment as usual on major depressive disorder: A meta-analysis","volume":"210","author":"S Kolovos","year":"2017","journal-title":"J Affect Disord"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","article-title":"The STAR* D Project results: A comprehensive review of findings","volume":"9","author":"D Warden","year":"2007","journal-title":"Curr Psychiatry Rep"},{"key":"ref9","first-page":"e188","article-title":"Effect of inadequate response to treatment in patients with depression","volume":"16","author":"R L Knoth","year":"2010","journal-title":"Am J Manag Care"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1176\/appi.ajp.2012.12020250","article-title":"Increase in work productivity of depressed individuals with improvement in depressive symptom severity","volume":"170","author":"M H Trivedi","year":"2013","journal-title":"Am J Psychiatry"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/da.20505","article-title":"Nonresponse, partial response, and failure to achieve remission: Humanistic and cost burden in major depressive disorder","volume":"26","author":"J A Mauskopf","year":"2009","journal-title":"Depress Anxiety"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jad.2018.06.045","article-title":"The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature","volume":"242","author":"K M Johnston","year":"2019","journal-title":"J Affect Disord"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/01.pra.0000450317.76117.62","article-title":"Clinical and functional outcomes of patients who experience partial response to citalopram: secondary analysis of STAR*D","volume":"20","author":"E B Dennehy","year":"2014","journal-title":"J Psychiatr Pract"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S2215-0366(19)30483-3","volume":"7","year":"2020","journal-title":"The Lancet Psychiatry"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamapsychiatry.2013.286","article-title":"Incorporating multidimensional patient-reported outcomes of symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression to measure treatment impact and recovery in MDD","volume":"70","author":"R M Cohen","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/acps.12301","article-title":"Quality of life in major depressive disorder before\/after multiple steps of treatment and one-year follow-up","volume":"131","author":"W W IsHak","year":"2015","journal-title":"Acta Psychiatr Scand"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/YIC.0b013e328303ac5f","article-title":"Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder","volume":"23","author":"K Demyttenaere","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"key":"ref19","first-page":"142","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder","volume":"27","author":"R W Lam","year":"2015","journal-title":"Ann Clin Psychiatry"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2147\/NDT.S156619","article-title":"Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: A meta-analysis of randomized controlled trials","volume":"14","author":"S Luan","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.4088\/JCP.14r09204","article-title":"Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: Systematic review and network meta-analysis","volume":"76","author":"X Zhou","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40263-012-0032-z","article-title":"Clinical issues in use of atypical antipsychotics for depressed patients","volume":"27","author":"C-U Pae","year":"2013","journal-title":"CNS Drugs"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e1001403","DOI":"10.1371\/journal.pmed.1001403","article-title":"Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta-analysis of depression, quality of life, and safety outcomes","volume":"10","author":"G I Spielmans","year":"2013","journal-title":"PLoS Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1477-7525-10-81","article-title":"Comparison of health-related quality of life among patients using atypical antipsychotics for treatment of depression: Results from the National Health and Wellness Survey","volume":"10","author":"I Kalsekar","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/NDT.S146840","article-title":"Functioning outcomes with adjunctive treatments for major depressive disorder: A systematic review of randomized placebo-controlled studies","volume":"14","author":"E Weiller","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"18m12202","DOI":"10.4088\/JCP.18m12202","article-title":"Symptomatic and functional outcomes and early prediction of response to escitalopram monotherapy and sequential adjunctive aripiprazole therapy in patients with major depressive disorder: A CAN-BIND-1 report","volume":"80","author":"S H Kennedy","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12888-016-0785-x","article-title":"Discovering biomarkers for antidepressant response: Protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort","volume":"16","author":"R W Lam","year":"2016","journal-title":"BMC Psychiatry"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5455\/msm.2019.31.14-18","article-title":"Quality of life assessment in antidepressant treatment of patients with depression and\/or anxiety disorder","volume":"31","author":"A Dzevlan","year":"2019","journal-title":"Mater Sociomed"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.2174\/138161212803523635","article-title":"The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in response prediction","volume":"18","author":"S H Kennedy","year":"2012","journal-title":"Curr Pharm Des"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"S A Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"ref31","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"D V Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fninf.2018.00028","article-title":"Brain-CODE: A secure neuroinformatics platform for management, federation, sharing and analysis of multi-dimensional neuroscience data","volume":"12","author":"A L Vaccarino","year":"2018","journal-title":"Front Neuroinform"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2850.2011.01735.x","article-title":"Quality of Life Enjoyment and Satisfaction Questionnaire \u2013 short form for quality of life assessments in clinical practice: A psychometric study","volume":"18","author":"D Stevanovic","year":"2011","journal-title":"J Psychiatr Ment Health Nurs"},{"key":"ref34","first-page":"321","article-title":"Quality of life enjoyment and satisfaction questionnaire: A new measure","volume":"29","author":"J Endicott","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/aje\/kwr193","article-title":"The PhenX Toolkit: get the most from your measures","volume":"174","author":"C M Hamilton","year":"2011","journal-title":"Am J Epidemiol"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.1002\/9780470024522","volume-title":"Quality of Life: The Assessment, Analysis and Interpretation of Patient-reported Outcomes","author":"P M Fayers","year":"2007","edition":"2nd ed."},{"key":"ref37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","article-title":"Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA)","volume":"192","author":"J B Williams","year":"2018","journal-title":"Br J Psychiatry"},{"key":"ref39","first-page":"1096","article-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","journal-title":"J Am Stat Assoc"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.psychres.2006.09.008","article-title":"Quality of life of \u201cnormal\u201d controls: Association with lifetime history of mental illness","volume":"152","author":"D Schechter","year":"2007","journal-title":"Psychiatry Res"},{"key":"ref41","first-page":"8","article-title":"Major depression comorbid with medical conditions: analysis of quality of life, functioning, and depressive symptom severity","volume":"48","author":"W W IsHak","year":"2018","journal-title":"Psychopharmacol Bull"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.genhosppsych.2003.07.004","article-title":"Quality of life assessments in major depressive disorder: A review of the literature","volume":"26","author":"G I Papakostas","year":"2004","journal-title":"Gen Hosp Psychiatry"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1176\/appi.ajp.162.6.1171","article-title":"Quality-of-life impairment in depressive and anxiety disorders","volume":"162","author":"M H Rapaport","year":"2005","journal-title":"Am J Psychiatry"},{"key":"ref44","first-page":"43","article-title":"Health-related quality of life in depression: A STAR*D report","volume":"22","author":"E J Daly","year":"2010","journal-title":"Ann Clin Psychiatry"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1192\/bjp.bp.115.175059","article-title":"Effect of psychotherapy for depression on quality of life: Meta-analysis","volume":"209","author":"S Kolovos","year":"2016","journal-title":"Br J Psychiatry"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1017\/S0033291716002774","article-title":"The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: A meta-analysis","volume":"47","author":"K Kamenov","year":"2016","journal-title":"Psychol Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1176\/appi.ajp.163.1.148","article-title":"How should remission from depression be defined? The depressed patient's perspective","volume":"163","author":"M Zimmerman","year":"2006","journal-title":"Am J Psychiatry"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jad.2013.05.048","article-title":"Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D)","volume":"151","author":"W W Ishak","year":"2013","journal-title":"J Affect Disord"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.comppsych.2004.07.002","article-title":"Psychosocial impairment and recurrence of major depression","volume":"45","author":"D A Solomon","year":"2004","journal-title":"Compr Psychiatry"},{"key":"ref50","first-page":"p 241","volume-title":"Quality of life and major depression","author":"M T Berlim","year":"2007"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1948550609359707","article-title":"Establishing causality using longitudinal hierarchical linear modeling: An illustration predicting achievement from self-control","volume":"1","author":"A L Duckworth","year":"2010","journal-title":"Soc Psychol Personal Sci"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1037\/1082-989X.11.2.142","article-title":"Conceptualizing and testing random indirect effects and moderated mediation in multilevel models: New procedures and recommendations","volume":"11","author":"D Bauer","year":"2006","journal-title":"Psychol Methods"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/sim.3180","article-title":"Placebo effect-adjusted assessment of quality of life in placebo-controlled clinical trials","volume":"27","author":"J C Eickhoff","year":"2008","journal-title":"Stat Med"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4306\/pi.2014.11.4.371","article-title":"A meta-analysis comparing open-label versus placebo-controlled clinical trials for aripiprazole augmentation in the treatment of major depressive disorder: Lessons and promises","volume":"11","author":"C-U Pae","year":"2014","journal-title":"Psychiatry Investig"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cpr.2009.01.005","article-title":"The importance of functional impairment to mental health outcomes: A case for reassessing our goals in depression treatment research","volume":"29","author":"P E McKnight","year":"2009","journal-title":"Clin Psychol Rev"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1385-0263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T22:39:24Z","timestamp":1631659164000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1385-0263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":52,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2021,9,14]]},"published-print":{"date-parts":[[2021,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1385-0263","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"type":"print","value":"0176-3679"},{"type":"electronic","value":"1439-0795"}],"subject":[],"published":{"date-parts":[[2021,3,2]]}}}